Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure

(2021) Suzanne Arends et al.   Lancet Rheumatology

Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases

(2020) Peter Blomgren et al.   ACS Medicinal Chemistry Letters

Tirabrutinib: First Approval

(2020) Sohita Dhillon   DRUGS

Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases

(2020) Javier Narváez et al.   Scientific Reports

Treatment of Sjögren’s syndrome: current therapy and future directions

(2019) Robert I Fox et al.   RHEUMATOLOGY

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials

(2019) Renaud Felten et al.   AUTOIMMUNITY REVIEWS

Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment

(2019) Frederick B. Vivino et al.   CLINICAL IMMUNOLOGY

EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

(2019) Manuel Ramos-Casals et al.   ANNALS OF THE RHEUMATIC DISEASES

Transcription profiling of peripheral B cells in antibody-positive primary Sjögren's syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature

(2018) J. Imgenberg-Kreuz et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Health-related quality of life and costs in Sjögren’s syndrome

(2018) Samira T Miyamoto et al.   RHEUMATOLOGY

The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study

(2017) J. Antonio Aviña-Zubieta et al.   JOURNAL OF RHEUMATOLOGY

Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease

(2017) Odilia B. J. Corneth et al.   Arthritis & Rheumatology

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

(2017) Simon J. Bowman et al.   Arthritis & Rheumatology

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis

(2013) A. L. Rankin et al.   JOURNAL OF IMMUNOLOGY

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

How Placebos Change the Patient's Brain

(2010) Fabrizio Benedetti et al.   NEUROPSYCHOPHARMACOLOGY

Cytokines in Sjögren’s syndrome

(2009) N Roescher et al.   ORAL DISEASES

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

(2008) Frances Rena Bahjat et al.   ARTHRITIS AND RHEUMATISM